Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01151527 · ClinicalTrials.gov registry record
Peripheral Blood Biomarkers in Idiopathic Interstitial Pneumonias
A clinical trial, sponsored by Duke University.
- Terminated
- Registry status
- 269
- Enrollment target
NCT01151527: Clinical Trial study, sponsored by Duke University.
NCT01151527 is a clinical trial that was terminated before completion, run by Duke University. The registered enrollment target is 269 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01151527 was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- 269 participants
- Enrollment target
Study Summary
We hypothesize that a peripheral blood biomarker or biological signature (gene or protein expression pattern) of idiopathic interstitial pneumonias (IIPs) will simplify and improve the accuracy of diagnosis of IIP and diagnose individuals at an earlier, more treatable, stage of their disease.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 269 participants |
| Start Date | 2010-04 |
| Est. Completion | 2013-02 |
Why NCT01151527 stopped before completion
NCT01151527 is an observational study that tracks outcomes without assigning an intervention. The registered 269 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01151527 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01151527 about?
NCT01151527 is a clinical study titled "Peripheral Blood Biomarkers in Idiopathic Interstitial Pneumonias". We hypothesize that a peripheral blood biomarker or biological signature (gene or protein expression pattern) of idiopathic interstitial pneumonias (IIPs) will simplify and improve the accuracy of diagnosis of IIP and diagnose individuals at an earlier, more treatable, stage of their disease.
What is the current status of trial NCT01151527?
This trial is currently terminated. The enrollment target is 269 participants. The study started on 2010-04. Estimated completion is 2013-02.
Who is sponsoring clinical trial NCT01151527?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04802291 · 269 participants · NA
HomeStyles-2: Shaping HOME Environments and LifeSTYLES to Prevent Childhood Obesity
- NCT06500455 · 269 participants · Phase 3
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
- NCT06630676 · 269 participants · NA
The Ability of Chronic Pain Patients to Self-diagnose Their Chief Source of Low Back Pain
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia